A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (BEACON)
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
Sponsor: Kodiak Sciences Inc
A PHASE3 clinical study on Macular Edema and Retinal Vein Occlusion, this trial is completed. The trial is conducted by Kodiak Sciences Inc and has accumulated 10 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2022 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 5 earlier versions
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Jul 2022 [monthly]
Recruiting PHASE3
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Sep 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kodiak Sciences Inc
For direct contact, visit the study record on ClinicalTrials.gov .